Implementation of the HUGO™ RAS system for robot-assisted radical prostatectomy: a single-center comparison with the da Vinci Xi® system.
- 1Department of Urology, University Medical Center Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. [email protected].
- 2Institute of Medical Biometry and Statistics, University of Luebeck, Luebeck, Germany.
- 3Department of Urology, University Medical Center Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany.
Abstract
Purpose
To compare early perioperative and pathological outcomes between the HUGO™ RAS and da Vinci Xi® robotic platforms for robot-assisted radical prostatectomy (RARP) at a single center.Methods
We retrospectively analyzed 107 consecutive patients who underwent RARP (50 HUGO™, 57 da Vinci™) between April 2024 and December 2025, performed by two surgeons who both used both systems. Outcome-specific propensity score models with overlap weighting were used to estimate adjusted associations between platform and operative duration, length of hospital stay, anastomotic integrity, positive surgical margins, lymph node yield, complications, and achieved nerve sparing.Results
Baseline characteristics were broadly comparable, although the HUGO™ cohort included a higher proportion of high-risk D'Amico tumors. Operative duration was longer with HUGO™ in the unadjusted analysis (211 vs. 193 min, p = 0.036); after overlap weighting and covariate adjustment, the difference was 14.6 min (95% CI -3.0 to 32.2) and not statistically significant. No statistically significant adjusted differences were observed between platforms for length of hospital stay, anastomotic integrity, positive surgical margins, lymph node yield, complications, or achieved nerve sparing.Conclusion
In this early single-center experience, RARP performed with the HUGO™ RAS system showed no statistically significant differences in early perioperative and pathological outcomes compared with the established da Vinci Xi® platform after adjustment for measured confounders. Larger prospective multicenter studies with longer follow-up are needed to confirm these findings and to evaluate long-term oncological and functional outcomes.
Related
- Robot-Assisted Radical Prostatectomy Using the Hugo RAS System: The First 15 Cases by a First-Year Novice Surgeon Without Prior Console Experiences.
- Association of preoperative frailty with health-related quality of life and urinary function after robot-assisted radical prostatectomy
- Feasibility and early outcomes of salvage robot-assisted radical prostatectomy after focal therapy failure for localized prostate cancer
- Bacterial Meningitis Following Robot-Assisted Radical Prostatectomy After Neoadjuvant Precision Oncology-Directed Therapy: A Case Report.
- Latent psychological resilience profiles and their association with physical resilience in older patients after robot-assisted radical prostatectomy: a cross-sectional study
BibTeX
@article{moderegger2026implementation,
title = {{Implementation of the HUGO™ RAS system for robot-assisted radical prostatectomy: a single-center comparison with the da Vinci Xi® system.}},
author = {Anton Moderegger and Reinhard Vonthein and Hendrik Eike Fender and Alexander Stephan Reese and Friederike Praus and Marie Christine Roesch and Axel S Merseburger and Daniar Osmonov},
journal = {World journal of urology},
year = {2026},
month = oct,
doi = {10.1007/s00345-026-06870-8},
url = {https://europepmc.org/article/MED/42955349},
note = {CC BY},
}
RIS
TY - JOUR
TI - Implementation of the HUGO™ RAS system for robot-assisted radical prostatectomy: a single-center comparison with the da Vinci Xi® system.
AU - Anton Moderegger
AU - Reinhard Vonthein
AU - Hendrik Eike Fender
AU - Alexander Stephan Reese
AU - Friederike Praus
AU - Marie Christine Roesch
AU - Axel S Merseburger
AU - Daniar Osmonov
PY - 2026
DA - 2026/10/28
JO - World journal of urology
DO - 10.1007/s00345-026-06870-8
UR - https://europepmc.org/article/MED/42955349
AB - Purpose To compare early perioperative and pathological outcomes between the HUGO™ RAS and da Vinci Xi® robotic platforms for robot-assisted radical prostatectomy (RARP) at a single center.Methods We retrospectively analyzed 107 consecutive patients who underwent RARP (50 HUGO™, 57 da Vinci™) between April 2024 and December 2025, performed by two surgeons who both used both systems. Outcome-specific propensity score models with overlap weighting were used to estimate adjusted associations between platform and operative duration, length of hospital stay, anastomotic integrity, positive surgical margins, lymph node yield, complications, and achieved nerve sparing.Results Baseline characteristics were broadly comparable, although the HUGO™ cohort included a higher proportion of high-risk D'Amico tumors. Operative duration was longer with HUGO™ in the unadjusted analysis (211 vs. 193 min, p = 0.036); after overlap weighting and covariate adjustment, the difference was 14.6 min (95% CI -3.0 to 32.2) and not statistically significant. No statistically significant adjusted differences were observed between platforms for length of hospital stay, anastomotic integrity, positive surgical margins, lymph node yield, complications, or achieved nerve sparing.Conclusion In this early single-center experience, RARP performed with the HUGO™ RAS system showed no statistically significant differences in early perioperative and pathological outcomes compared with the established da Vinci Xi® platform after adjustment for measured confounders. Larger prospective multicenter studies with longer follow-up are needed to confirm these findings and to evaluate long-term oncological and functional outcomes.
SN - 0724-4983
SN - 1433-8726
ER -